Gianluca Fuggetta - 21 Mar 2024 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Principal Accounting and Financial Officer
Signature
/s/ Matthias Alder, Attorney-In-Fact
Issuer symbol
GANX
Transactions as of
21 Mar 2024
Net transactions value
$0
Form type
4
Filing time
25 Mar 2024, 21:30:15 UTC
Previous filing
27 Mar 2023
Next filing
21 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Employee Stock Option (right to buy) Award $0 +50,000 $0.000000 50,000 21 Mar 2024 Common Stock 50,000 $4.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest 25% on March 21, 2025 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.

Remarks:

Principal Accounting and Financial Officer